Guangdong Food and Drug Administration announced the list of 17 third-party pharmaceutical modern logistics enterprises

Yesterday (August 1st), Guangdong Food and Drug Administration announced 17 “lists of third-party pharmaceutical modern logistics companies”. As early as March 24 this year, the Guangdong Provincial Bureau announced 23 “lists of third-party medical equipment modern logistics enterprises”. 11 of the 17 companies announced this time have the qualification of third-party medical equipment logistics. The 11 companies are Sinopharm Holding Guangzhou Co., Ltd., Guangzhou Pharmaceutical Co., Ltd., Guangdong Jiuzhou Tong Pharmaceutical Co., Ltd., Guangdong General Pharmaceutical Co., Ltd., Guangzhou Qingping Pharmaceutical Logistics Co., Ltd., Chuangmei Pharmaceutical Co., Ltd., China Resources Guangdong Pharmaceutical Co., Ltd. Guangdong Pharmaceutical Group Co., Ltd., Guangdong Shenhua Pharmaceutical Co., Ltd., Dongguan Guangji Pharmaceutical Co., Ltd., Guangdong Hengfu Pharmaceutical Co., Ltd.

Strong competition from third-party pharmaceutical logistics

Since last year, with the strong entry of SF into the field of pharmaceutical cold chain distribution, traditional pharmaceutical circulation companies and third-party logistics companies have been short-lived, and competition will be inevitable.

In February 2016, the State Council issued the “Decision on the Second Batch of Cancellation of 152 Centrally Appointed Local Administrative Execution Items”, and the third-party drug logistics business no longer needs to be examined and approved. This is seen as a “starting gun” for third-party logistics to enter the pharmaceutical industry.

At the same time, the "Shandong Vaccine Incident" triggered the concern of the whole society for the cold chain logistics of drugs. For SF, which started out with fresh express delivery and has an advantage in cold chain logistics, it seems that it is a good time to enter the pharmaceutical cold chain logistics business.

In fact, as early as March 2014, SF established the Pharmaceutical Logistics Division and invested a lot of resources to explore the pharmaceutical logistics business. In 2016, the Cold Transport Division was established to separate the pharmaceutical cold chain and the fresh cold chain. "We hope to enhance the comprehensive logistics service capabilities of SF Express through the development of pharmaceutical logistics, especially the cold chain business." SF Medical Logistics staff said in an interview.

Ma Jiancong, director of pharmaceutical sales at SF Refrigeration Division, said that as of May this year, SF Cold Chain Medicine Ground Transportation Network has run through 21 city networks, 22 trunk lines and 462 flows. The cold chain transporter can realize the fixed-point start-up and provide customers with multi-batch and small-batch LTL logistics services according to the properties of the drugs and the temperature and humidity requirements. He revealed that in the next three years, SF plans to build 6-7 medical supply chain core logistics centers to achieve warehousing capacity covering the whole country.

Another third-party logistics company, China Post, has also made a difference in the field of pharmaceutical logistics. In 2015, China Post Fujian Post Bureau funded the establishment of a holding pharmaceutical logistics company, which was then directly managed by Beijing Zhongyou Asset Management Co., Ltd. The company has the basic drug distribution qualifications of the provincial and Fuzhou public medical institutions, and has established a business team in the seven procurement areas of Fujian to carry out the integrated distribution of the basic and non-based medicines in the county and township, intended to carry out the distribution coverage of the grassroots market. . In the pharmaceutical cold chain transportation business, China Post has also been involved.

For the third-party logistics companies, especially SF's strong entry, the traditional pharmaceutical circulation companies have a subtle attitude. Many small and medium-sized enterprises have expressed fears and panic, while the logistics giants represented by Sinopharm and Kyushutong have been unsettled.

Yao Gong, the general manager of the Kyushu Cold Chain Business Unit, said that the current national pharmaceutical cold chain logistics scale is about 5 billion yuan. The service providers are mainly traditional pharmaceutical logistics companies, so they are not worried about the intervention of SF, Sinopharm Relevant people also expressed the same view to reporters.

Third-party medical devices are still on the road

Unlike third-party drug distribution, third-party logistics companies of medical devices, as important participants in the circulation of medical devices, do not have a relatively complete regulatory system in China.

In 2014, the “Measures for the Supervision and Administration of Medical Device Management” was promulgated. For the first time, the third-party logistics management of medical devices was clearly instructed at the regulatory level, and it has been used up to now: 1. Under certain conditions, medical device operating enterprises may not be established. Warehouse, all products are entrusted to other medical equipment business enterprises for storage;

2. If a medical device operating enterprise entrusts other units to transport medical devices, it shall evaluate and evaluate the quality assurance capability of the carrier's transportation medical devices, clarify the quality responsibility during transportation, and ensure the quality and safety during transportation;

3. If a medical device operating enterprise provides storage and distribution services for other medical device production and operation enterprises, it shall sign a written agreement with the entrusting party to clarify the rights and obligations of both parties, and have equipment and facilities that are compatible with the product storage and distribution conditions and scale. The client conducts real-time electronic data exchange and realizes the computer information management platform and technical means traceable throughout the whole process of product operation.

Isavuconazole Intermediates

Dingmin Pharmaceutical supply Isavuconazole API and Isavuconazole Intermediates with high purity and best price. The main products CAS No are as follows:241479-67-4, 241479-73-2, 241479-74-3, 368421-58-3. Sample can be sent if you request.

Welcome to do business with us. Please email to us directly.

Cas 368421-58-3,Isavuconazole Intermediates,2-Amine Hydrochloride

Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com